Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196936 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
A Phase 2 study of Breast Cancer, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 13
- Study locations
NCT01196936: Active Phase 2 study of Breast Cancer, sponsored by University of Alabama at Birmingham.
NCT01196936 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 84 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196936, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 13
- Study locations
Study Summary
Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer survivors.
Primary Outcome
Mammographic density was quantified as percentage of fibroglandular tissue. Using an intention-to-treat analysis, mammographic breast density (MBD) was compared between patients in the low dose tamoxifen intervention and placebo group by applying the linear mixed effects model for normally distributed data.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER immunohistochemistry staining method
- DRUG Tamoxifen Citrate
- PROCEDURE Digital mammography
- OTHER pharmacological study
Study Locations (13)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
California
- City of Hope Medical Center - Duarte
Colorado
- University of Colorado, Anschutz Medical Campus - Aurora
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-09 |
| Est. Completion | 2028-12-11 |
| Phase | Phase 2 |
What the registry record for NCT01196936 still lists
NCT01196936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01196936 lists 13 locations in 12 states (Minnesota, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT01196936 about?
NCT01196936 is a clinical study titled "Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors". Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer ...
What is the current status of trial NCT01196936?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2010-09. Estimated completion is 2028-12-11.
What conditions does trial NCT01196936 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01196936?
The interventions under investigation include: Placebo (DRUG), immunohistochemistry staining method (OTHER), Tamoxifen Citrate (DRUG), Digital mammography (PROCEDURE), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT01196936?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01196936 being conducted?
This trial has 13 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01196936's enrollment target sits among peer trials
84 633rd of 1224 higher than 589 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia